J Korean Med Assoc > Volume 66(4); 2023 > Article |
|
Framingham risk of CVEs |
ENESTnd |
||
---|---|---|---|
Nilotinib 300 mga) | Nilotinib 400 mga) | Imatinib 400 mgb) | |
All CVEs | |||
CVEs occurrence before 5 yr | |||
<10% | 2.2 (4/178) | 4.0 (7/176) | 0.5 (1/182) |
≥10% to <20% | 12.2 (5/41) | 19.2 (10/52) | 4.1 (2/49) |
≥20% | 15.0 (6/40) | 28.9 (11/38) | 3.0 (1/33) |
CVEs occurrence after 5 yr | |||
<10% | 8.7 (10/115) | 15.2 (19/125) | 1.1 (1/94) |
≥10% to <20% | 28.0 (7/25) | 48.5 (16/33) | 17.4 (4/23) |
≥20% | 33.3 (8/24) | 33.3 (7/21) | 4.8 (1/21) |
Values are presented as % (number/total number).
Modified from Kantarjian HM, et al. Leukemia 2021;35:440-453, according to the Creative Commons license [10].
CVE, cardiovascular event.
Ponatinib |
Asciminib |
|||||
---|---|---|---|---|---|---|
PACE [18] |
OPTIC [19] |
STAMP [25] |
||||
Ponatinib 45 mga) | Ponatinib 45 mga) | Ponatinib 30 mga) | Ponatinb 15 mga) | Asciminib 40 mgb) | Bosutinib 500 mga) | |
All CVEs | 31.1 (84/270)c) | 9.6 (9/94) | 5.3 (5/94) | 3.2 (3/94) | 5.1 (8/156) | 1.3 (1/76) |
HTN | 36.7 (99/270)c) | 27.7 (26/94) | 26.6 (25/94) | 23.4 (22/94) | 13.5 (21/156) | 5.3 (4/76) |
Values are presented as % (number/total number).
Based on Cortes JE, et al. Blood 2018;132:393-404, Cortes J, et al. Blood 2021;138:2042-2050, and Hochhaus A, et al. Leukemia 2023;37:617-626, according to the Creative Commons license [18,19,25]
PACE, Ponatinib Ph+ ALL and CML Evaluation; OPTIC, Optimizing Ponatinib Treatment in CP-CML; STAMP, Specifically Targets the ABL Myristoyl Pocket; CVE, cardiovascular event; HTN, hypertension; CML-CP, chronic myeloid leukemia-chronic phase.